Drugs for Insulin-Like Growth Factor I (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 25)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Mecasermin |
Approved, Investigational |
Phase 3 |
|
68562-41-4 |
|
Synonyms:
CEP-151
Human somatomedin C
IGF1
IGF-1
INCRELEX
INSULIN-LIKE GROWTH FACTOR 1
INSULIN-LIKE GROWTH FACTOR I
|
MECASERMIN
MECASERMIN RECOMBINANT
MECASERMIN RINFABATE
Mecasermina
MECHANO GROWTH FACTOR
MYOTROPHIN
SOMATOMEDIN-C
|
|
2 |
|
Caseins |
|
Phase 2, Phase 3 |
|
|
|
3 |
|
Insulin, Globin Zinc |
|
Phase 3 |
|
|
|
4 |
|
Insulin |
|
Phase 3 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
5 |
|
Mitogens |
|
Phase 3 |
|
|
|
6 |
|
Cetuximab |
Approved |
Phase 2 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
7 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
8 |
|
Irinotecan |
Approved, Investigational |
Phase 2 |
|
97682-44-5, 100286-90-6 |
60838 |
Synonyms:
(+)-Irinotecan
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Biotecan
Camptosar
Camptothecin 11
Camptothecin-11
CP0
CPT 11
CPT11
CPT-11
HSDB 7607
Irinophore C
IRINOTECAN
|
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
NK012 Compound
sn 38
sn-38
sn38 CPD
|
|
9 |
|
Oxaliplatin |
Approved, Investigational |
Phase 2 |
|
61825-94-3 |
43805 11947679 6857599 |
Synonyms:
ACT 078
ACT-078
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
Elplat
Foloxatine
JM-83
L-OHP
L-OHP CPD
MBP-426 (LIPOSOMAL OXALIPLATIN)
NSC-266046
Oxalatoplatin
|
Oxalatoplatinum
Oxaliplatin
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
RP-54780
SR-96669
Transplatin
|
|
10 |
|
Vitamins |
|
Phase 2 |
|
|
|
11 |
|
topoisomerase I inhibitors |
|
Phase 2 |
|
|
|
12 |
|
Cola |
|
Phase 2 |
|
|
|
13 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
14 |
|
Hormones |
|
Phase 2 |
|
|
|
15 |
|
Hydrocortisone succinate |
Approved |
Early Phase 1 |
|
2203-97-6 |
3643 |
Synonyms:
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadec-6-en-14-yl}-2-oxoethoxy)-4-oxobutanoate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl}-2-oxoethoxy)-4-oxobutanoate
Cortisol 21-(hydrogen succinate)
Cortisol succinate
HYDROCORTISONE HEMISUCCINATE
|
Hydrocortisone hemisuccinate anhydrous
Hydrocortisone hydrogen succinate
HYDROCORTISONE SUCCINATE
Hydroxycortisone succinate
NSC-7576
|
|
16 |
|
Hydrocortisone acetate |
Approved, Vet_approved |
Early Phase 1 |
|
50-03-3 |
|
Synonyms:
21-O-acetylcortisol
BARQUINOL HC
CHLOROMYCETIN HYDROCORT
COLIFOAM
CORTEF ACETATE
CORTIFOAM
Cortisol 21-acetate
CORTRIL
CORTUCID
DRICORT
EPIFOAM
FRAMYCORT
FUCIDIN H
GENTICIN HC
GENTISONE HC
|
GPPE EAR SUSP
GPPE EYE CRM
GPPE FOAM AERO
HC45 HYDROCORT
HEMSOL-HC
HEPACORT PLUS
HYDROCAL
HYDROCORTISONE 21-ACETATE
HYDROCORTISONE ACETATE
HYDROCORTONE
LANACORT
MICORT-HC
NEO-CORTEF
NSC-741
ORABASE HCA
|
|
17 |
|
Hydrocortisone |
Approved, Vet_approved |
Early Phase 1 |
|
50-23-7 |
3640 5754 |
Synonyms:
(11ALPHA,14BETA)-11,17,21-TRIHYDROXYPREGN-4-ENE-3,20-DIONE
(11b)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11Β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(1S,2R,10S,11S,14S,15S,17S)-14,17-DIHYDROXY-14-(2-HYDROXYACETYL)-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
11 Epicortisol
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b,17a,21-Trihydroxy-4-pregnene-3,20-dione
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11-beta-Hydrocortisone
11beta-Hydroxycortisone
11-beta-Hydroxycortisone
11b-Hydrocortisone
11b-Hydroxycortisone
11-Epicortisol
11-Hydrocortisone
11Β,17α,21-trihydroxy-4-pregnene-3,20-dione
11Β-hydrocortisone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
17-Hydroxycorticosterone
4-Pregnen-11b,17a,21-triol-3,20-dione
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnen-11β,17α,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
ACETASOL HC
ACTICO МИХАИЛRT
Acticort
Acticort®|Efmody®|Plenadren®
Aeroseb HC
Aeroseb-HC
Alacort
Ala-cort
Ala-scalp
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort-HC
ANUGESIC HC
Anusol HC
ANUSOL PLUS HC
ANUSOL SOOTHING RELIEF
Anusol-HC
Aquacort
Aquanil HC
Balneol-HC
Barseb HC
Basan-corti
Beta-HC
b-HC
CaldeCORT spray
CALMURID HC
CANESTEN HC
Cetacort
Chronocort
CIPRO HC
Clear aid
Cleiton
Cobadex
Colocort
Compound F
CORLAN
Cor-oticin
Cortanal
Cor-tar-quin
Cort-dome
Cortef
CORTENEM
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisolonum
Cortisporin
Cortisporin otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cort-quin
CORTRIL
Cremesone
Cremicort-H
Cutisol
DAKTACORT
DAKTACORT HYDROCORT
Delacort
DERMA CARE HYDROCORT
Dermacort
Derm-aid
DERMASPRAY DEMANG
Dermil
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
ECONACORT
Ef corlin
Efcorbin
Efcortelan
EFCORTELAN P
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
EURAX-HC
EURAX-HYDROCORT
Evacort
EXE-CORT
Ficortril
Fiocortril
Flexicort
Foille insetti
Genacort
GERMOLOIDS HC
Glycort
GREGODERM
gyno-Cortisone
HC
|
HC #1
HC #4
HC (HYDROCORTISONE)
HC45
H-Cort
Heb cort
Heb-cort
Hi-cor
Hidalone
hidro-Colisona
Hidrocortisona
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
hydro-Adreson
hydro-Colisona
Hydrocort
HYDROCORT IN CALAMINE OILY
HYDROCORT IN CETOMACROGOL FOR A
HYDROCORT IN WTE SOFT PARAF
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone acetate
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone butyrate
Hydrocortisone free alcohol
Hydrocortisone in absorbase
Hydrocortisone sodium phosphate
Hydrocortisone valerate
Hydrocortisone, (11 alpha)-isomer
Hydrocortisone, (9 beta,10 alpha,11 alpha)-isomer
Hydrocortisonum
Hydrocortistab
Hydrocortisyl
HYDROCORTONE
HYDRODERM
HYDRODERM HC
hydro-RX
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone lotion
Idrocortisone
Incortin-H
Incortin-hydrogen
JUNGLE FOR
Kendall's compound F
Komed HC
Kyypakkaus
Lacticare HC
Lacticare-HC
Lactisona
Locoid
Lubricort
Maintasone
Medicort
Meusicort
Micort-HC
Mildison
MILDISON LIPOCREAM
Milliderm
neo-Cort-dome
neo-Cortef
Neosporin-H ear
Nogenic HC
NSC-10483
Nutracort
NYBADEX
Nystaform-HC
Ophthocort
Optef
Otalgine
Otic-neo-cort-dome
Otobiotic
Otocort
OTOSEPTIL
Otosone-F
OTOSPORIN
Pediotic suspension
Penecort
PERINAL
Permicort
Plenadren
Polcort H
Preparation H hydrocortisone cream
Prepcort
Prestwick_265
Prevex HC
Proctocort
PROCTOCREAM HC
Proctofoam
PROCTOFOAM HC
PROCTOSEDYL
Protocort
QUINOCORT
Racet
Rectoid
Reichstein's substance m
Remederm HC
Sanatison
Scalpicin capilar
Schericur
Scheroson F
SENTIAL HC
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral hydrocort
Tarcortin
Terra-cortril
TERRA-CORTRIL NYSTATIN
Texacort
Timocort
TIMODINE
Topicort
TOPISONE
Transderma H
Traumaide
TRI-CICATRIN
U-cort
Uniderm
UNIROID
UNIROID HC
Vioform-hydrocortisone
VoSol HC
Vytone
XYLOPROCT
Zenoxone
β-HC
|
|
18 |
|
Zinc cation |
Approved, Experimental, Investigational |
|
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
19 |
|
Morphine |
Approved, Investigational |
|
|
57-27-2 |
5288826 |
Synonyms:
(-)-Heroin hydrochloride
(-)-Morphine
(−)-MORPHINE
(5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5a,6a)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5Α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5Α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
ANHYDROUS MORPHINE
Apokyn
Astramorph PF
AVINZA
Chloride, morphine
Contin, MS
D-(-)-Morphine
DEPODUR
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dulcontin
Duramorph
Duramorph PF
Duromorph
Epimorph
Heroin hydrochloride
Heroine hydrochloride
IDS-NM-009
INFUMORPH
KADIAN
l-Morphine
M.O.S
Meconium
M-Eslon
Morfina
Morfina dosa
|
Morphia
Morphin
Morphina
MORPHINE
Morphine chloride
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine sulfate
Morphine sulfate (2:1), anhydrous
Morphine sulfate (2:1), pentahydrate
morphine sulfate|Ms Contin®|Oramorph®
Morphinism
Morphinum
Morphitec
Morphium
Moscontin
MS Contin
MS/L
MS/S
MSIR
N02AA01
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
ORAMORPH
Oramorph SR
Ospalivina
Rescudose
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
Statex
Statex Drops
Substitol
Sulfate, morphine
|
|
20 |
|
Endothelial Growth Factors |
|
|
|
|
|
21 |
|
Hormone Antagonists |
|
Early Phase 1 |
|
|
|
22 |
|
Hydrocortisone 17-butyrate 21-propionate |
|
Early Phase 1 |
|
|
|
23 |
|
Hypoglycemic Agents |
|
|
|
|
|
24 |
|
Androgens |
|
|
|
|
|
25 |
|
Pharmaceutical Solutions |
|
|
|
|
|
Interventional clinical trials:
(show all 30)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa |
Completed |
NCT01823822 |
Phase 2, Phase 3 |
|
2 |
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With Primary IGF-1 Deficiency: A Multi-Center, Open Label, Concentration-Controlled Study |
Completed |
NCT00125190 |
Phase 2, Phase 3 |
rhIGF-1 (mecasermin) for a period of 86 weeks |
3 |
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Prepubertal Children With Growth Failure Associated With Primary IGF-1 Deficiency: A Phase 3, Randomized, Open Label, Observation-Controlled, Multicenter, Parallel-Dose Comparison Trial |
Completed |
NCT00125164 |
Phase 3 |
rhIGF-1 (mecasermin, Tercica, Inc.) |
4 |
Recombinant Human Insulin-Like Growth Factor-1 (IGF-1) Treatment of Children With Growth Failure Associated With Primary IGF-1 Deficiency: An Open-Label, Multi-Center, Extension Study |
Terminated |
NCT00330668 |
Phase 3 |
rh IGF-1 (mecasermin) |
5 |
A Placebo Controlled, Randomized, Double-Blind Phase II Clinical Trial to Evaluate Tolerability, Safety and Efficacy Endpoints After Administration of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) for 24 Weeks in Adults With Myotonic Dystrophy Type 1 |
Completed |
NCT00577577 |
Phase 2 |
rhIGF-I/rhIGFBP-3;placebo |
6 |
Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism |
Completed |
NCT00004700 |
Phase 2 |
insulin-like growth factor I |
7 |
A 90-day, Double-blind, Placebo-controlled, Randomized, Parallel-Group Efficacy and Safety Study of an Amino Acid Supplement in Adults |
Recruiting |
NCT05599282 |
Phase 2 |
Amino Acid Supplement |
8 |
Chinese Medicine WT for Elevating IGF-1 of Patients With Spinocerebellar Ataxia Type 3 - Pilot Study |
Recruiting |
NCT05038306 |
Phase 2 |
Chinese medicine WT |
9 |
A Randomized Phase II Clinical Trial Investigating Irinotecan Plus Cetuximab With or Without Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody (IMC-A12) for the Treatment of Patients With Metastatic K-Ras Wild Type Carcinoma of the Colon or Rectum That Has Progressed on Oxaliplatin and Bevacizumab Given as First-Line Therapy |
Terminated |
NCT00845039 |
Phase 2 |
Irinotecan |
10 |
Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 rhIGF-1) Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency: A Six-year, Randomized, Multi-center, Open-label, Parallel-group, Active Treatment Controlled, Dose Selection Trial |
Terminated |
NCT00572156 |
Phase 2 |
NutropinAq® (Somatropin [rDNA origin]);Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]) |
11 |
Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 Administered Every Other Week in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available |
Completed |
NCT00785941 |
Phase 1 |
|
12 |
Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available |
Completed |
NCT00785538 |
Phase 1 |
|
13 |
A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors |
Completed |
NCT00880282 |
Phase 1 |
temsirolimus |
14 |
A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors |
Withdrawn |
NCT01182883 |
Phase 1 |
IMC-A12;Temsirolimus |
15 |
Effect of maternalBMI and Type of Infants Feeding on IGF-1in Infants as Early Marker of Childand Adult Hood Obesity |
Unknown status |
NCT03275272 |
|
|
16 |
Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy |
Unknown status |
NCT01718015 |
|
|
17 |
Effect of Training and Local Infusion of Insulin-like Growth Factor-I and Training on Tendon Structure in Patients With Patellar Tendinopathy |
Unknown status |
NCT01834989 |
Early Phase 1 |
Insulin-like growth factor I;Placebo |
18 |
The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons |
Unknown status |
NCT00969644 |
|
Somatropin;Pegvisomant |
19 |
Genetic Study of Insulin-Like Growth Factor-I Receptor Mutations in Patients With Intrauterine Growth Retardation |
Unknown status |
NCT00005105 |
|
|
20 |
The Role of Insulin-like Growth Factor-I (IGF-I) and Free Fatty Acids in Insulin Resistance, Insulin Secretion and Glucose Metabolism Abnormalities in Acromegaly |
Completed |
NCT02084095 |
|
|
21 |
Effects of Low Dose Growth Hormone (GH) Therapy on Insulin Sensitivity, Adipocyte Insulin-like Growth Factor-I (IGF-I) and IGF-I/Insulin Receptor Density and Regulation of Cortisol Metabolism in GH Deficient Adults |
Completed |
NCT00517062 |
Early Phase 1 |
Growth hormone (Genotropin);Placebo |
22 |
Contribution of Insulin-Like Growth Factor-I (IGF-I) and Its Binding Protein (IGFBP3) to Increased Left Ventricular Mass in Familial Hypertrophic Cardiomyopathy Caused by Distinct Sarcomeric Mutations |
Completed |
NCT00001878 |
|
|
23 |
Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance |
Completed |
NCT00004419 |
|
insulin-like growth factor I |
24 |
Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism |
Completed |
NCT00004699 |
|
insulin-like growth factor I |
25 |
Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism |
Completed |
NCT00004825 |
|
recombinant human insulin-like growth factor I |
26 |
A Study to Assess and Quantify Surface Insulin-like Growth Factor I Receptor (IGF-IR) in Rhabdomyosarcoma (RMS) Tumor Tissue |
Completed |
NCT01365962 |
|
|
27 |
The Influence of Androgen Receptor, Insulin Like Growth Factor 1 Receptor, and Insulin Receptor in Male Patients With Peripheral Artery Disease |
Recruiting |
NCT04710186 |
|
|
28 |
Effect of a High Interval Intensity Training Program on Quality of Life, Mental Health, Brain Executive Functions, and IGF-1 Response in Sedentary Young University Women. |
Recruiting |
NCT05642169 |
|
|
29 |
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD). |
Recruiting |
NCT00903110 |
|
Increlex® |
30 |
An Epidemiologic, Descriptive and Cross-sectional Study of the IGF-1, IGFBP-3 and ALS Normative Ranges in a Healthy Paediatric Spanish Population, Divided Into Chronological Age, Sex and Pubertal Stage |
Terminated |
NCT01676090 |
|
|
|